XML 59 R34.htm IDEA: XBRL DOCUMENT v3.20.4
Organization and Summary of Significant Accounting Policies (Narrative) (Details)
12 Months Ended
Jan. 01, 2021
USD ($)
product
segment
$ / shares
Jan. 03, 2020
USD ($)
Dec. 28, 2018
USD ($)
Organization And Summary Of Significant Policies [Line Items]      
Number of operating segments | segment 1    
Selling, general and administrative $ 293,355,000 $ 228,244,000 $ 206,366,000
Impairment charge on goodwill $ 0    
Percent discount for prompt payment 2.00%    
Discount expected to be earned 100.00%    
Medicare Part D funding mandate 70.00%    
Advertising expense $ 25,100,000 $ 17,900,000 $ 14,800,000
Net foreign currency gains and losses $ 900,000    
Collaborative Arrangement with GlaxoSmithKline      
Organization And Summary Of Significant Policies [Line Items]      
Cost of goods sold is related to product 3.00%    
Maximum      
Organization And Summary Of Significant Policies [Line Items]      
Estimated useful lives 15 years    
Final Calculation Of Branded Prescription Drug Fee      
Organization And Summary Of Significant Policies [Line Items]      
Selling, general and administrative $ 5,100,000    
Decrease in earnings per share due to change in accounting estimate (in dollars per share) | $ / shares $ (0.02)    
Resulting From Discovery Efforts      
Organization And Summary Of Significant Policies [Line Items]      
Number of products that entered in the commercial marketplace | product 4    
Products Derived from Cabozantinib      
Organization And Summary Of Significant Policies [Line Items]      
Number of products that entered in the commercial marketplace | product 2    
Products Derived From Other Compounds      
Organization And Summary Of Significant Policies [Line Items]      
Number of products that entered in the commercial marketplace | product 2